Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine

Fig. 4

The CI in HL-60 and the 3 drug-resistant cell lines. The CI values were calculated after the cells had been exposed to nucleoside analogs (ara-C/CAFdA) or inhibitors (venetoclax/alvocidib) or both simultaneously. The CI values of less than, equal to, and more than 1 indicate synergy, additivity, and antagonism, respectively. a Combination of ara-C/CAFdA and venetoclax. HL-60-1; ara-C and venetoclax, HL-60-2; CAFdA and venetoclax, HL-60/ara-C10; ara-C and venetoclax, HL-60/CAFdA4; CAFdA and venetoclax, HL-60/CAFdA30; CAFdA and venetoclax. b Combination of ara-C/CAFdA and alvocidib. HL-60-1; ara-C and alvocidib, HL-60-2; CAFdA and alvocidib, HL-60/ara-C10; ara-C and alvocidib, HL-60/CAFdA4; CAFdA and alvocidib, HL-60/CAFdA30; CAFdA and alvocidib

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us